CTLA4 and melanoma: Notably, neutralization of endogenous activin A by a soluble form of ActR-IIB sensitized melanoma grafts to combined anti-PD1/anti-CTLA4 blockade, supporting the clinical potential of targeting activin A to improve responses to immunotherapy in melanoma (168).